A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome

63Citations
Citations of this article
95Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients at least three months after SARS-CoV-2 infection and; 3) symptomatic patients at least 3 months after SARS-CoV-2 infection with chronic fatigue syndrome or similar symptoms, here designated as patients with long COVID-19 syndrome (LCS). Multiplex cytokine profiling indicated slightly elevated pro-inflammatory cytokine levels in recovered individuals in contrast to patients with LCS. Plasma proteomics demonstrated low levels of acute phase proteins and macrophage-derived secreted proteins in LCS. High levels of anti-inflammatory oxylipins including omega-3 fatty acids in LCS were detected by eicosadomics, whereas targeted metabolic profiling indicated high levels of anti-inflammatory osmolytes taurine and hypaphorine, but low amino acid and triglyceride levels and deregulated acylcarnitines. A model considering alternatively polarized macrophages as a major contributor to these molecular alterations is presented.

Author supplied keywords

Cite

CITATION STYLE

APA

Kovarik, J. J., Bileck, A., Hagn, G., Meier-Menches, S. M., Frey, T., Kaempf, A., … Gerner, C. (2023). A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome. IScience, 26(1). https://doi.org/10.1016/j.isci.2022.105717

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free